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Abstract
Background: Corneal cross-linking is widely used to treat keratoconus. However, to date, only limited data from
randomized trials support its efficacy.
Methods: The efficacy and safety of corneal cross-linking for halting progression of keratoconus were investigated
in a prospective, randomized, blinded, placebo controlled, multicentre trial. Twenty-nine keratoconus patients
were randomized in three trial centres. The mean age at inclusion was 28 years. Longitudinal changes in corneal
refraction were assessed by linear regression. The best corrected visual acuity, surface defects and corneal
inflammation were also assessed. These data were analysed with a multifactorial linear regression model.
Results: A total of 15 eyes were randomized to the treatment and 14 to the control group. Follow-up averaged
1098 days. Corneal refractive power decreased on average (+/−standard deviation) by 0.35 +/− 0.58 dioptres/year in
the treatment group. The controls showed an increase of 0.11 +/− 0.61 dioptres/year. This difference was statistically
significant (p = 0.02).
Conclusions: Our data suggest that corneal cross-linking is an effective treatment for some patients to halt the
progression of keratoconus. However, some of the treated patients still progressed, whereas some untreated controls
improved. Therefore, further investigations are necessary to decide which patients require treatment and which do not.
Trial registration: NCT00626717, Date of registration: February 20, 2008.
Background
Keratoconus is a progressive corneal disease that leads
to alterations in the overall shape of the cornea and
eventual thinning and scarring, with subsequent de-
creases in vision [1]. The genetic and environmental
contributions to the pathogenesis of keratoconus remain
controversial [2, 3]. For example, associations with gen-
etic disorders like Down’s syndrome [4] and influences
of atopic dermatitis and eye rubbing have been described
[5]. Keratoconus usually starts during adolescence and
progresses until the third or fourth decade of life [6, 7].
The CLEK (Collaborative Longitudinal Evaluation of
Keratoconus) Study [8] showed a mean change in flatter
keratometry readings of 1.6 dioptres in the natural
course of keratoconus progression over an eight year
period, where higher rates of progression occurred in
younger than in older patients. Furthermore, an increase
of more than 3 dioptres in spherical equivalent was
observed in 24.1 % of patients with risk factors for high
progression, such as young age and poor high-contrast
visual acuity [8].
The intention of the corneal cross-linking (CXL) pro-
cedure using riboflavin is to halt the progression of kera-
toconus. The induction of covalent molecular cross-links
in corneal tissue using riboflavin and UVA-Radiation
* Correspondence: stefan.lang@uniklinik-freiburg.de
1Eye Center, Albert-Ludwigs-University of Freiburg, Killianstr. 5, 79106 Freiburg,
Germany
Full list of author information is available at the end of the article
© 2015 Lang et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lang et al. BMC Ophthalmology  (2015) 15:78 
DOI 10.1186/s12886-015-0070-7
was first described by Spoerl et al. in porcine corneas in
1998 [9]. In vitro experiments have since shown that
CXL leads to changes in the thermo-mechanical behaviour
of the cornea [10], the collagen fibre diameter [11, 12], the
resistance to enzymatic digestion [13] and the corneal
thickness [14]. In addition, apoptosis and loss of kerato-
cytes have been observed [15].
The method was clinically introduced in 2003 with a
non-randomized pilot study in 22 patients [16]. In this
prospective pilot study, Wollensak et al. reported a halt
in the progression in all treated eyes [16]. Since then,
many more non-randomized studies, case series or co-
hort studies [17–23] have demonstrated similar results,
with the largest trial being that of Raiskup-Wolf et al.,
which included 241 eyes [18].
Four promising randomized controlled trials of corneal
cross-linking were performed in the past. Wittig-Silva et
al. first published interim results of an Australian trial in
2008 which showed a stabilization of all treated eyes
[24]. The final results with 46 patients in the treatment
group and 48 patients in the control group demon-
strated an improvement in maximal keratometric power
(Kmax) and visual acuity in the treated patients, while
the untreated patients showed further keratoconus pro-
gression [25]. A second randomized controlled trial per-
formed by Hersh et al. included eyes with keratoconus
and post-lasik ectasia [26], as well as a sham treatment
group that received corneal cross-linking after three
months. All patients were aware of their randomly
assigned groups. An improvement in uncorrected and
corrected visual acuity, as well as the topographic mea-
surements was reported in the treatment group. After
one-year follow-up, an overall improvement in corneal
shape was observed [27]. A third randomized controlled
study, conducted by O’Brart in 24 patients, demon-
strated an improvement in in corrected visual acuity,
Orbscan simulated and keratometry simulated astigma-
tism [28]. The control group consisted of the fellow eyes.
Sharma et al. performed the fourth study—a prospective
randomized controlled trial in an Asian population with
a total of 43 patients. A decrease was observed in the
maximum and minimum keratometry in the cross-
linking group in this study [29].
The safety of cross-linking has also been assessed in
various trials. The removal of the epithelium can lead to
the occurrence of bacterial keratitis [30], corneal melting
[31], haze [32], corneal endothelial loss [33] and even
calcific band keratopathy [34]. A study by Greenstein et
al. described an increase in haze up to three months
after treatment, followed by a decrease up to month 12
[32]. Koller et al. described an overall complication rate
of 2.9 % in a prospective trial and identified risk factors
such as patient age of more than 35 years and a visual
acuity better than 20/25 [35].
The efficacy and safety of corneal cross-linking has
been suggested by different authors, but clear proof of a
therapeutic effect is not available through a placebo-
controlled study with an independent control group
[36]. Therefore, we investigated the efficacy of corneal
cross-linking with riboflavin in halting the progression
of keratoconus by conducting a placebo-controlled,
randomized, blinded, multicentric clinical trial that in-
cluded an independent control group.
Methods
This study was performed at three university eye
hospitals—in Freiburg, Munich and Würzburg—and was
registered at cliniclatrials.gov (NCT00626717). Ethics
Committee approval was obtained at Albert-Ludwigs-
University of Freiburg, Ludwig-Maximilians-University,
Munich and University Hospital Würzburg. Written
informed consent was obtained from the patient, or in
case of minors, from the parent or legal guardian.
Research adhered to the tenets of the Declaration of
Helsinki.
Inclusion and exclusion criteria
The inclusion criteria for this study were keratoconus at
an early stage, defined as correction of refractive error
possible with spectacles or contact lenses. The progres-
sion had to be either proven by measurement of the
corneal topography (an increase of more than 1 dioptre
in Kmax within one year) or by a clinically significant
change in refraction. The change in refraction was
defined as a change in spectacle correction or change in
contact lens parameters. Exclusion criteria were patient
age under 12 years, corneal thickness below 450 μm,
further pre-existing ocular diseases, prior ocular surgery,
pregnancy and allergy to riboflavin. Written informed
consent was obtained prior to participation.
The initial examination included best corrected visual
acuity, slit lamp examination and ophthalmoscopy and
assessment of corneal topography with the Orbscan II
system (Bausch & Lomb) at the Freiburg centre or with
the Pentacam (OCULUS Optikgeräte GmbH) at the
Munich and Würzburg centres. The change in kerato-
metric corneal refraction was the primary evaluation and
every measurement on each patient was done using the
same topography system; consequently, we only assessed
the longitudinal changes. Systematic errors due to the ker-
atometry measurements by different systems are therefore
unlikely. Computerized randomization was performed at
the coordinating centre in Freiburg. Randomization was
stratified by centre and the randomizations were submit-
ted via fax. The patients were either randomized to the
treatment or the placebo group. On the same day, the
worse eye was treated either with a standard CXL protocol
[16] or with a sham procedure. The worse eye was defined
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as the eye with a greater progression, or steeper K-values
in case of equal progression in both eyes. The CXL was
performed according to an established protocol, as
follows: corneal epithelial removal, 0.1 % riboflavin eye
drops (MedioCROSS H Riboflavin > 0,1 %, Medio-Haus
Medizinprodukte GmbH, Kiel) every two minutes for
30 min, and UVA 370 nm at 3 mW/cm2 for 30 min with
continued application of 0.1 % riboflavin eye drops every
two minutes. The sham procedure consisted of application
of fluorescein eye drops every two minutes for 30 min, ra-
diation with visible blue light for 30 min and no epithelial
removal.
Follow-up
Postoperative slit-lamp examinations were scheduled at
days 1, 3, 5 and 7 after the intervention. Examinations
included best corrected visual acuity and slit lamp exam-
ination, as well as ophthalmoscopy and corneal topog-
raphy. Topography assessment was repeated three times
each visit and the averaged K-values were entered into
the case report forms. Examination was performed on
days 14, 30 and 90 as well as months 6, 9, 12, 18, 24 and
36 post intervention.
The controls were easily identifiable during the first 4
visits since the epithelium was not removed. Therefore,
a second examiner, who had not participated in the
treatment or the first examinations, took over follow-up
examinations from the 5th visit on to achieve a blinding
of the examiner. The patients were informed about pos-
sible symptoms of dry eye and pain due to epithelial re-
moval. However, patients were not informed about the
connection of these symptoms with the placebo or CXL
treatment. The patients therefore were not fully aware of
their assignment to the placebo or CXL group. The use
of contact lenses was not restricted.
Clinical endpoints and statistics
The primary end-point was progression of keratoconus.
An increase of 1 dioptre per year in patients younger
than 20 years and an increase of 0.2 dioptres per year in
the complete cohort was considered as progression
according to the data of the natural course of the disease
from the CLEK Study. This was measured by the
longitudinal change in keratometric corneal refraction
(maximum simulated K-readings) and calculated by li-
near regression over the steeper K-readings plotted
against follow-up time for each patient. Sample size was
calculated to ensure detection of a halting of the spon-
taneous progression rate from the CLEK study [37]. Ac-
cording to the CLEK study, we assumed a progression
risk of 30 % within two years. A one-year recruiting time
and minimum follow up of two years were expected. A
two-sample t-test power calculation estimated a statis-
tical power of 80 % with a total sample size of 65
patients per group. Unfortunately, this was not achieved,
since most candidates were either non-progressive or re-
luctant to undergo randomization. Therefore, we closed
the trial after recruitment of 30 patients. As secondary
endpoints, we also assessed the minimal simulated
K-readings, the central corneal thickness, worsening of
best corrected visual acuity and the occurrence of
further adverse events. The trial was originally analysed
according to the intention-to-treat principle. Because we
did not stratify randomization for age in the protocol,
we opted for a multiple linear regression model with
group assignment and age at inclusion to control for
these potential confounders.
Results
The consort chart is depicted in Fig. 1. One patient had to
be excluded prior to randomization since the inclusion
criteria were not fulfilled, leaving 29 patients available for
analysis. Of these, 15 patients had documented progression
of keratoconus; the remaining 14 patients had reported
visual deterioration or worsening of spectacle refraction.
The mean age at inclusion was 28 years (median range: 17
to 53). In total, 15 patients were randomized to the treat-
ment and 14 to the control group. Follow-up averaged 1098
(quartiles 802 to 1131) days. Baseline and follow-up
characteristics of the treatment and control group are
summarized in Table 1. Three patients had an incom-
plete follow-up and did not participate in further exam-
inations after one year; one of these three belonged to
the treatment arm, the other two to the placebo group.
Four patients in the treatment group showed a slight
steepening of their corneal topography. Eleven patients
showed a slight flattening or remained stable. In the
control group, eight patients showed steepening and six
patients showed flattening of the simulated maximum
K-reading (Table 1, Fig. 2). In the treatment group the
corneal refractive power (Kmax) decreased in mean
(+/−standard deviation) by 0.35 +/− 0.58 dioptres per year.
The control-group showed an increase of 0.11 +/− 0.61
dioptres per year (Fig. 2). This difference was statistically
significant (p = 0.02) in the multiple linear regression
model. Considering our definition of progression, two
patients in the placebo group and one patient in the
treatment group showed a clinically significant progres-
sion. The corneal refractive power showed an increase of
1.5 dioptres per year in a 38-year-old patient.
The preoperative central corneal thickness was 468 +/−
25.36 μm in the control group and 466 +/− 27.76 μm in
the treatment group. Three years after the intervention,
the control group corneal thickness was 467 +/−
23.95 μm and the treatment group thickness was 449
+/−71.96 μm; this difference was not statistically
significant. All secondary endpoints are summarized in
Table 2.
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None of the patients sustained bacterial keratitis or
subepithelial infiltrates or had to undergo any kind of
surgery after the intervention.
During the complete follow-up period, eight patients
experienced a significant worsening of the best corrected
visual acuity: four in the control group and four in the
treatment group (Table 3). Chi-square test showed no
statistical difference.
All eyes in the treatment group had postoperative
epithelial defects due to the epithelial removal during
surgery. In the placebo group, three eyes developed
epithelial defects after the intervention probably due to
drying of the ocular surface despite intensive eye drop
application during the process. The treatment group
showed significantly more haze (15 of 15 patients) than
was observed in the control group (four of 15 patients,
p < 0.001, Table 1). After three years, all but three eyes
showed a complete resolution of the haze (Table 3).
Discussion
A limitation of our study is its sample size, which was
considerably smaller than planned. The patients were in-
creasingly unwilling to be randomized against sham pro-
cedures. We eventually had to terminate the recruitment
period after recruitment stalled. For this reason, our
study includes only 30 patients and not the anticipated
number of 120. However, we strongly believe that our
results are of interest because equally-sized unbiased
data can no longer be collected these days.
This is one of the first randomized, double-blind,
placebo-controlled multicentre clinical trials to inves-
tigate the efficacy of riboflavin CXL to halt keratoconus
progression. The control group underwent a sham
Fig. 1 Consort flow-chart. Three patients had an incomplete follow-up of one year. The data were included in the analysis. One patient belonged
to the treatment arm, the other two to the placebo group






Female Patients 14 % (2) 27 % (4) p = 0.41
Age at inclusion 25.8 +/−7.4 29.5 +/−11.1 p = 0.55
Centre: Freiburg 64 % (9) 40 % (6) p = 0.10
München 36 % (5) 33 % (5)
Würzburg 0 % (0) 27 % (4)
Corneal thickness
at inclusion
468.8 +/−25.4 466.8 +/−27.8 p = 0.91
Kmin at inclusion 46.5 +/−4.3 44.0 +/−1.7 p = 0.07
Kmax at inclusion 50.9 +/−5.7 47.3 +/−2.2 p = 0.05
Visual acuity at
inclusion (logMAR)
0.39 +/−0.37 0.25 +/−0.15 p = 0.38
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procedure and did not comprise the fellow eyes of the
treated patients. This is especially important since kera-
toconus is an asymmetric disease [38]. The study re-
ported by O’Brart et al. used a control group without
sham treatment, consisting of the fellow eye of the 24
study patients. Randomization was performed to account
for asymmetric progression. Only three eyes of 24 in the
control group showed a slight deterioration in the inves-
tigated parameters and the majority of the untreated
eyes remained stable [28]. Intra-individual controls,
without sham treatment or blinding, were also used
by Wittig-Silva et al. [24, 25], whose data showed
stabilization of all treated eyes compared to progression
in the fellow eyes. The trial by Hersh et al. included a
control group that underwent a sham procedure. The
patients were aware of their assigned group. Keratoco-
nus in this group remained stable and no significant
changes were noted in any of the investigated corneal
indices or in best corrected visual acuity. However, a
crossover to the treatment group was performed three
months after placebo treatment [26]. This group also
showed no significant changes in corneal indices or best
corrected visual acuity at the time of conversion. A trial
by Sharma et al. included a control group with a sham
procedure. Epithelial debridement was also performed in
the sham group. Similar to our study, this trial showed a
significant decrease in Kmax in the cross-linking group.
Additional confocal analysis of the epithelial healing and
the regeneration of the sub epithelial plexus was per-
formed in this study [29].
Blinding the patients in the present study was challen-
ging due to its design. Patients of the CXL arm were
more likely to suffer from postoperative pain in com-
parison to the controls. To address this, we educated all
patients that postoperative pain can occur but not at a
100 % rate. Nevertheless, we cannot fully rule out that
some patients were possibly aware of their treatment
arm. Our opinion, however, is that this did not introduce
any systematic bias.
Despite its low power, the study also confirms that
CXL can significantly alter the steepening of the topo-
graphic K-readings in keratoconus patients, since the
Fig. 2 Corneal refractive power for each patient over the time of the follow-up
Table 2 Secondary endpoints: corneal thickness, maximal and
minimal simulated K-readings and visual acuity in the placebo
and treatment (CXL) group at the end of the trial
Placebo group CXL group
Corneal thickness (μm)
at the end of follow-up
467.3 +/−24 449.2 +/−72 p = 0.96
Kmin (dpt) at the end
of follow-up
46.1 +/−4.7 43.5 +/−1.7 p = 0.59
Kmax (dpt) at the end
of follow-up
51.2 +/−6.9 46.9 +/−2.1 p = 0.59
Visual acuity (logMAR)
at the end of follow-up
0.23 +/−0.27 0.22 +/−0.14 p = 0.61
Table 3 Adverse events in both groups. The treatment (CXL)
group showed significantly more haze and corneal erosion
during the follow-up period. After 3 years, all but 3 eyes showed
a complete resolution of the haze
Placebo group CXL group
Maximal haze 0 71 % (10) 0 % (0) p < 0.01
1 7 % (1) 20 % (3)
2 21 % (3) 73 % (11)
3 0 % (0) 7 % (1)
Corneal erosions 0 79 % (11) 7 % (1) p < 0.01
1 0 % (0) 7 % (1)
2 7 % (1) 13 % (2)
3 7 % (1) 60 % (9)
4 7 % (1) 13 % (2)
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overall maximum K-reading decreased by 0.35 +/− 0.58
dioptres per year. This finding was adjusted for age, a
well-known risk factor for progression of keratoconus.
However, four of the 15 patients in the treatment group
showed an increase in Kmax from 0.02 to 0.32 dioptres
per year. The age of these patients ranged from 19 to
38 years. Six of 14 patients in the control group showed
no steepening of any kind in their corneal topographies.
Moreover, the remaining eight patients in this group all
suffered only from a mild to moderate steepening of the
topographic K-readings, so that only two of the controls
finally fulfilled our criteria for the progression of kerato-
conus. Incidentally, one of these two patients had the
highest slope and by far the highest simulated maximum
K-reading of more than 65 dioptres. Since this patient
was assigned to the control group, this might represent
a bias in our study. However, omission of this patient
from the statistical analysis still reveals a significant
difference between both groups (data not shown).
In the treatment group, four patients showed a slight
steepening of their corneal topographies. One of these
patients fulfilled our criteria for the progression of kera-
toconus. The reason why only a few of the control
patients maintained progression during the course of the
trial might be that, according to the protocol, the pro-
gression required for inclusion did not have to be proven
by keratometry. Another possible explanation is that the
noise of the tomography system that may render the
detection signs of progression impossible, especially in
patients with higher K-values or irregularities of the
surface [25, 39–41] or after use of contact lenses. We
sought to counteract this potential error by repeating
the measurements on each visit. Nevertheless, a small
inaccuracy of the keratometric K-readings cannot be
fully ruled out. The recent consensus states that the pro-
gression of keratoconus is best evaluated with additional
thickness and posterior keratometric data [42]; however,
this had not been established at the time of preparation
of the study protocol.
Some of the patients may have had a progression rate
that was lower than estimated. This limitation of our
study may be due to the fact that the patients did not
require a proven keratometric progression for enrolment
in the trial.
Not all enrolled patients had documented objective
progression. We therefore characterized this subgroup
to rule out confounding from this factor. Fifteen patients
were enrolled with objective documented progression,
whereas 14 patients only had subjective worsening. Of
those 14 patients, eight were in the treatment and six
were in the placebo group. The difference in slope of
Kmax was not statistically significant (p = 0.47) between
the patients with objective progression before recruit-
ment (−0.22 +/− 0.57 dioptres per year) and the patients
with subjective worsening (−0.03 +/−0.67 dioptres per
year). We added this possible confounder to the multiple
linear regression model. This factor missed statistical
significance (p = 0.39) and the treatment effect remained
statistically significant (p = 0.02).
The patient age may also account for the low progres-
sion rate observed in the study, especially since nine pa-
tients were above 30 years of age. This age group has
been shown to have only subtle changes in keratometry
[37]. However, this was also true for the treatment group
as a principle of randomization. The low rate of progres-
sion is incidentally concordant with the CLEK Study and
other CXL trials [24, 26, 28, 32]. Nevertheless, our study
found a slight, but statistically significant, superiority of
CXL over placebo treatment regarding the change in
corneal topography. This agrees with the findings of the
other prospective trials [24, 26, 27]. The absence of
progression in many untreated patients emphasises the
need for careful selection of suitable patients in order to
prevent overtreatment.
Since three patients were lost to follow-up, a higher
incidence of progression cannot be fully ruled out.
The change in visual acuity did not show a statistically
significant difference between the control and treatment
group. Even though the cross-linking group experienced
more haze, this obviously did not impair the visual acu-
ity of the patients, as also found by Greenstein et al.
[32]. The occurrence of haze after corneal cross-linking
has been described by several authors [32, 34]. The de-
crease in haze over a period of several months to years
is also confirmed. Three patients had remaining haze
three years after corneal cross-linking, but none of these
patients suffered any visual loss in comparison to their
vision before treatment. The absence of other more
severe complications shows that corneal cross-linking is
a safe therapeutic option for keratoconus.
Conclusions
Our randomized trial confirms a beneficial effect of CXL
with riboflavin and UVA radiation as a treatment for
progressive keratoconus that halts the changes in cor-
neal topography. We also found that some patients show
no worsening or progression of any kind, even without
treatment, and we observed a slight steepening in max-
imum K-readings despite CXL. The number of patients
needing treatment may therefore be higher than ex-
pected. Some patients might receive an overtreatment if
corneal cross-linking was performed and CXL seems to
be less effective in some patients than in others. There-
fore, in the future, we need to determine the clinical pa-
rameters that will allow for a distinction of keratoconus
patients who will benefit from the treatment and the
ones who will not.
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